A parametric analysis of olanzapine-induced weight gain in female rats

Psychopharmacology

Volumn 181, Issue 1, 2005, Pages 80-89

  Cooper, G D ^a   Pickavance, L C ^a   Wilding, J P H ^a   Halford, J C G ^a   Goudie, A J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adiponectin; Animal models; Antipsychotics; Diabetes; Insulin; Obesity; Olanzapine; Prolactin; Weight gain

Indexed keywords

ADIPONECTIN; GLUCOSE; INSULIN; OLANZAPINE; PROLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY FAT; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; METABOLIC DISORDER; NONHUMAN; OBESITY; PARAMETRIC TEST; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

ADIPOSE TISSUE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; EATING; ESTRADIOL; FEMALE; HOMEOSTASIS; HYPERINSULINISM; INSULIN RESISTANCE; LEPTIN; METABOLIC DISEASES; PROLACTIN; RATS; RATS, WISTAR; STATISTICS; WEIGHT GAIN;

EID: 26644458378     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-2224-4     Document Type: Article

References (64)

1. Allison D, Mentore J, Heo M, Chandler L, Cappelleri J, Infante M, Weiden P (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696
2. Almeras N, Despres J, Villeneuve J, Demers M, Roy M, Cadrin C, Mottard J, Bouchard R (2004) Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 65:557-564
3. Arjona A, Zhang S, Adamson B, Wurtman R (2004) An animal model of antipsychotic-induced weight gain. Behav Brain Res 152:121-127
4. Amer P (2003) The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 14:137-145
5. Asayama K, Hayashibe H, Dobashi K, Uchida N, Nakane T, Kodera K, Shirahata A, Taniyama M (2003) Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res 11:1072-1079
6. Baptista T, Mata A, Teneud L, de Quijada M, Wan H-W, Hernandez L (1998a) Effects of long term administration of clozapine on body weight and food intake in rats. Pharmacol Biochem Behav 45:51-54
7. Baptista T, Contreras Q, Teneud L, Albomoz M, Acosta A, Paez X, de Quijada M, La Cruz A, Hernandez L (1998b) Mechanism of the neuroleptic-induced obesity in female rats. Prog Neuropsychopharmacol Biol Psychiatry 22:187-198
8. Baptista T, Alvarez L, Lacruz A, de Mendoza S, Hernandez L (1999) Glucose tolerance and serum insulin levels in an animal model of obesity induced by sub-acute or chronic administration of antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 23:277-287
9. Baptista T, Araujo de Baptista E, Ng Ying Kin N, Beaulieu S, Walker D, Joober R, Lalonde J, Richard D (2002a) Comparative effects of the antipsychotics sulpiride or risperidone in rats I: bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res 957:144-151
10. Baptista T, Kin N, Beaulieu S, de Baptista E (2002b) Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35:205-219
11. Baptista T, Lacruz A, Paez X, Hernandez L, Beaulieu S (2002c) The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved? Eur J Pharmacol 447:91-98
12. Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X, Hernandez L (2004a) Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 5:279-299
13. Baptista T, Araujo de Baptista E, Lalonde J, Plamondon J, Ng Ying Kin NMK, Beaulieu S, Joober R, Richard D (2004b) Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Prog Neuropsychopharmacol Biol Psychiatry 28:1305-1311
14. Barzali N, She L, Liu B-Q, Vuguin P, Cohen P, Wang J, Rossetti L (1999) Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 48:94-98
15. Basson B, Kinon B, Taylor C, Szymanski K, Gilmore J, Tollefson G (2001) Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62:231-238
16. Benvenga N, Leander J (1997) Increased food consumption by clozapine but not olanzapine in satiated rats. Drug Dev Res 41:48-50
17. Caballero E (2003) Obesity, diabetes, and the metabolic syndrome: new challenges in antipsychotic therapy. CNS Spectr, 11(Suppl 2):19-22
18. Consensus Statement (2004) Consensus development conference on antipsychotic drugs and obesity. Obes Res 12:362-368
19. Daniels A, Grizzle M, Strole C, Ignar D, Jones DNC (2003) Antipsychotic-induced weight gain: effects of olanzapine and ziprasidone in female rats. J Psychopharmacol 17(3):A52, (abstract supplement)
20. Ebenbichler C, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A, Hummer M, Kemmler K, Lechleitner M, Patsch J, Fleischhacker W (2003) Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 64:1436-1439
21. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Fleischhacker W (2001) Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 158:1719-1722
22. Fell M, Marshall K, Williams J, Neill J (2004a) Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol 18:149-155
23. Fell M, Neil J, Marshall J (2004b) Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrus cycle and uterine weight in female rats. Eur Neuropsychopharmacol (in press)
24. Fitzgerald P, Scaffidi A, Morris M, de Castella A, Kulkarni J (2003) The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. Hum Psychopharmacol 18:551-557
25. Freedman R (2003) Schizophrenia. N Engl J Med 349:1738-1749
26. Gabriely I, Ma X, Yang X, Atzmon G, Rajala M, Berg A, Scherer P, Rossetti L, Barzali N (2002) Removal of visceral fat prevents insulin resistance and glucose intolerance of aging. Diabetes 51:2951-2958
27. Glick I, Fryburg D, O'Sullivan R, Siu C, Simpson G (2001) Ziprasidone's benefits versus olanzapine regarding weight and insulin resistance. Eur Neuropsychopharmacol 11(Suppl 3):S273
28. Goldfine A, Kahn C (2003) Adiponectin: linking the fat cell to insulin resistance. Lancet 362:1431-1432
29. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G, Weizman A, Apter A (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159:1055-1057
30. Goudie A, Smith J, Halford J (2002) Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol 16:291-296
31. Goudie A, Cooper G, Halford J (2005) Antipsychotic-induced weight gain. Diabetes Obes Metab (in press)
32. Green A, Patel J, Goisman R, Allison D, Blackburn G (2000) Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 22:224-235
33. Group Statement (2004) "Schizophrenia and diabetes" expert consensus meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry 184(Suppl 47):S112-S114
34. Hartfield A, Moore N, Clifton P (2003) Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology 167:115-122
35. Henderson D (2002) Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 16:77-89
36. Henderson D, Cagliero E, Gray C, Nasrallah R, Hayden D, Schoenfeld D, Goff D (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157:975-981
37. Holt R, Peveler R, Byrne C (2004) Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 21:515-523
38. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599
39. Jones B, Basson B, Walker D, Crawford A, Kinon B (2001) Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 62(Suppl 2):41-44
40. Kaur G, Kulkarni S (2002) Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Prog Neuropsychopharmacol Biol Psychiatry 26:277-285
41. Kraus T, Haack M, Schuld A, Hinze-Seich D, Kuhn M, Uhr M, Pollmacher T (1999) Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156:312-314
42. Lacruz A, Baptista T, de Mendoza S, Mendoza-Guillen J, Hernandez L (2000) Antipsychotic drug-induced obesity in rats: correlation between leptin, insulin and body weight during sulpiride treatment. Mol Psychiatry 5:70-76
43. Lee M, Clifton P (2002) Meal patterns of free feeding rats treated with clozapine olanzapine and haloperidol. Pharmacol Biochem Behav 71:147-154
44. Lerner V, Libov I, Kanevsksy M (2003) High dose olanzapine-induced improvement of pre-existing type 2 diabetes mellitus in schizophrenic patients. Int J Psychiatry Med 33:403-410
45. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R (1985) Homeostasis model assessment: insulin resistance and beta-cell function. Diabetologia 28:412-419
46. McIntyre R, Mancini D, Basile V, Srinivasan J, Kennedy S (2003) Antipsychotic-induced weight gain: bipolar disorder and leptin. J Clin Psychopharmacol 23:323-327
47. Melkersson K, Dahl M-L (2003) Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology 170:157-166
48. Melkersson K, Dahl M-L (2004) Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64:701-723
49. Melkersson K, Hulting A (2001) Insulin and leptin levels in patients with schizophrenia or related psychoses - a comparison between different antipsychotic agents. Psychopharmacology 154:205-212
50. Melkersson K, Hulting A, Brismar K (2000) Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61:742-749
51. Melkersson K, Dahl M-L, Hutling A-L (2004) Guidelines for the prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology (in press)
52. Meyer J, Koro C (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1-17
53. Nasrallah H (2003) A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 28(Suppl 1):83-96
54. Newcomer J, Haupt D, Fucetola R, Melson A, Schweiger J, Cooper B, Selke G (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337-345
55. Ota M, Mori K, Nakashima A, Kaneko Y, Fujiwara K, Itoh M, Nagasaka A, Ota A (2002) Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats. Clin Exp Pharmacol Physiol 29:980-989
56. Pickavance L, Buckingham R, Wilding J (2001) Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. Diabetes Obes Metab 3:171-180
57. Pouzet B, Mow T, Kreilgaard M, Velschow S (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 75:133-140
58. Ryan M, Thakore J (2002) Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 71:239-257
59. Sowell M, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg H, Breier A, Beasley C, Dananberg J (2002) Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 87:2918-2923
60. Thornton-Jones Z, Neill J, Reynolds G (2002) The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. J Psychopharmacol 16:35-37
61. Togo T, Kojima K, Shoji M, Kase A, Hirotake U, Katsuse O, Iseki E, Kosaka K (2004) Serum adiponectin concentrations during treatment with olanzapine and risperidone: a pilot study. Int Clin Psychopharmacol 19:37-39
62. Virkkunen M, Wahlbeck K, Rissanen A, Naukkarinen H, Franssila-Kallunki A (2002) Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study. Pharmacopsychiatry 35:124-126
63. Zarate J, Boksa P, Baptista T, Joober R (2004) Effects of clozapine on behavioral and metabolic traits relevant for schizophrenia in two mouse strains. Psychopharmacology 171:162-172
64. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmacher T (2003) Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 37:193-220